← Crinetics Pharmaceuticals, Inc. (CRNX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Crinetics Pharmaceuticals, Inc. (CRNX)
Pharmaceutical Preparations · market cap $9.0B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-08-15 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Crinetics Pharmaceuticals (CRNX) is a San Diego-based specialty pharma company focused on endocrine diseases, with a market cap of ~$8.8B on ~105M shares at ~$83.58. Its lead asset paltusotine is in Phase 3 for acromegaly, with a broader pipeline including atumelnant (Phase 3 in congenital adrenal hyperplasia) and CRN09682 (Phase 2 in SST2-positive neuroendocrine neoplasms). The company is pre-revenue in any meaningful sense, burning cash rapidly with a reported 2.8-month runway.
The catalyst path
- 2027-08-15 (est.)Phase 2 · CRN09682imp 7/10
- 2027-08-15 (est.)Phase 3 · Paltusotineimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Paltusotine | Phase 3 | Acromegaly |
| atumelnant (CRN04894) | Phase 2 | Congenital Adrenal Hyperplasia |
| Randomized: 40 mg Paltusotine | Phase 2 | Carcinoid Syndrome |
| Atumelnant | Phase 3 | Congenital Adrenal Hyperplasia |
| CRN09682 | Phase 2 | SST2-positive Neuroendocrine Neoplasms |
Price & technical context
3-month
+126.7%
6-month
+78.4%
12-month
+182.3%
52-wk range
$29.09–$84.95
vs 50-day MA
+35.1%
vs 200-day MA
+77.2%
Realized vol
88.1%
Max drawdown
-57.9%
Daily closes through 2026-09-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CRNX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.